Transformational month for MyFiziq as its shares hit $1.00
September has shaped up as a transformative month for health and wellness technology company MyFiziq Limited (ASX:MYQ).
For those unfamiliar with the company, MYQ has developed a patented mobile application that allows users to track body shapes and dimensions while performing everyday activities.
The application measures body fat indirectly through machine learning and body shape analysis.
It also utilises surrogate measures of a person's total body fat mass, such as BMI, waist circumference, waist to hip ratio and waist to height ratio. These surrogate methods have been significantly associated with non-communicable diseases directly correlated with obesity.
The company is focused on delivering its app to several key verticals worth collectively trillions of dollars including health and fitness, medical and insurance, corporate wellness, apparel, telehealth and mobile health.
The market seems to have cottoned on to the value of this technology recently, with its shares reaching the magic $1.00 milestone on Wednesday. To put that in perspective, the company was trading at just 11.5 cents in April this year.
Note, shares are currently back to 83 cents.
Since then, the company has released a raft of information related to agreements, technological advancements and major milestones.
The latest are the definitive agreements with Biomorphik Pty Ltd (Biomorphik), an Australian-based behavioural change and technology company that has developed a medical health and wellness platform as a bridge between medical and health/wellness with the aim of reducing health costs at all levels of society from the individual, to healthcare and insurance systems and governments.
As we reported yesterday, Biomorphik has found that consumers, corporations and governments have developed a better understanding of the value of a healthy lifestyle and its impacts on individuals, families, business and economies especially in the wake of the COVID-19 pandemic.
As such, Biomorphik is an excellent fit with MyFiziq’s body scan technologies.
Biomorphik and MyFiziq have commenced working together to build and release an initial product by 10 November, 2020.
Further news shapes MYQ’s big month
This month also saw MYQ sign its first Binding Term Sheet to expand the newly developed CompleteScan platform capabilities with Asia Pacific corporate wellness platform WellteQ into the $10 trillion global telehealth, corporate wellness and insurance market.
CompleteScan will be integrated into WellteQ’s personalised digital wellness and analytics platform in readiness for January 2021.
WellTeq’s existing corporate customers including Willis Towers Watson APAC, NIB, Bupa Australia, Toll Logistics, Credit Suisse and DBS Bank will be the first to experience the tech, before prospective clients and markets outside of APAC are targeted.
The expectation is that the CompleteScan platform will appeal to multiple verticals in telehealth, corporate wellness and insurance partners around the globe.
WellteQ provides a unique solution that will now combine its mental health, nutrition, activity and wellness capabilities with the power of CompleteScan.
Bosanac was quick to highlight the significance of combining the technologies in saying, “This will be a world first as multiple organisations worldwide are positioning themselves with offerings to the corporate wellness space.
‘’Combining our new CompleteScan technology with WellteQ will be a paradigm shift in both tracking and analytic capabilities across multiple market segments.”
Read the full story: MyFiziq and WellteQ’s integrated offering seen as paradigms shift
This month also saw MYQ make a transformational change to its on-device capabilities, after it completed a successful integration into the Apple HealthKit with all dimensional captures from MyFiziq’s technology.
Apple Health is the central repository for all health and fitness data on iOS.
Since its launch in 2014, iOS users have been able to configure and prioritise their applications and accessories to send the data that matters to their lifestyle and fitness goals to the Apple Health app.
From this aggregated data, Apple is able to summarise health information related to activity, nutrition and various other health related metrics.
MyFiziq successfully completed the integration and sharing of all data captured through its platform into the MyFiziq and CompleteScan application with the Apple HealthKit environment.
MyFiziq can enable its partners to augment their current shareable data beyond just activity, removing the need for users to manually track their body circumference and composition measurements.
MyFiziq has achieved this by including a means to share anthropometric and body composition measures including body fat percentage, lean body mass, and waist circumference directly from a partner's app into Apple Health.
With Apple Health's API allowing a user to grant both ‘read and write’ access to their data, partner applications will be provided the opportunity to aggregate and interpret insights that previously would have been unattainable.
Furthermore, the addition of Nuralogix's facial scan as part of MyFiziq’s CompleteScan application will further extend the offering to be able to capture heart rate, heart rate variability and blood pressure, thereby unlocking additional insights and potential risks.
MyFiziq will be working with its partners as they leverage the possibilities of Apple's Health ecosystem, and the company will now commence subsequent integrations with Google Fit and Samsung Health.
These most recent developments could be the catalyst for further upside as MYQ continues to build out the capabilities of its increasingly sought after health and wellness technology.
Not to mention, the critical development in train at the moment that could see it dual listed on the NASDAQ in the not-too-distant future.
When the experts at Next Investors have a stock pick, it may pay to listen.
The Next Investors have been investing in ASX small cap stocks for years, with their best small cap picks yielding returns of 1,200%, 1,120%, 900% and 678%.
They have just revealed their hand-picked, FY2021 stock portfolio of high conviction long-term investments.
Click the link below to see what they are currently investing in.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.